Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 35 Biotech VC (Venture Capital) Funds in Norway in July 2025

Last updated: Jul 2025 A list of 35 VC (Venture Capital) funds that invest in Biotech startups based in Norway. We rank investors based on the number of investments they made in Biotech companies from Norway. We update this investor list every month.

Top 35 Biotech VC (Venture Capital) Funds in Norway in July 2025

Investor	Biotech Norway investments
Investinor	10
Birk Venture	5
SINTEF Venture AS	3
Hadean Ventures	3
Sarsia Seed Management	2
Meneldor	2
Lekh Corp AS	1
ERM Invest	1
Sofinnova Partners	1
ProVenture	1
Skyfall Ventures	1
Sarsia	1
Gezina	1
Nordic Impact	1
Bakken & Baeck	1
Norselab	1
World Wildlife Fund	1
Norwegian Research Council	1
Dynamk Capital	1
Canica	1
CoFounder	1
Coalition for Epidemic Preparedness Innovations	1
Glastad Invest	1
TeleVenture Management	1
PAACS Invest AS	1
DNB	1
Forbion Capital Partners	1
Project Sandwater	1
Advent Life Sciences	1
SR One	1
Protonic Partners	1
Advent Venture Partners	1
Innovations Kapital	1
Teknoinvest	1
HealthCap	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.

Investment focus

Software, Biotechnology, Manufacturing
Funding Round, Seed, Series A
Norway, United States, Switzerland

Portfolio highlights

Calluna Pharma — Join Calluna Pharma to transform therapeutics for inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, we can revolutionize patient care.
Ignite — A powerful & easy spend management tool to accelerate your procurement success by bringing clarity, clean data & sophisticated analytics to your fingertips
Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.

Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.

Investment focus

Biotechnology, Medical, Health Care
Seed, Series A, Funding Round
Norway, United Kingdom

Portfolio highlights

APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

We commercialize technology created by SINTEF's research environments

Investment focus

Manufacturing, Software, Energy
Seed, Funding Round, Pre-Seed
Norway, United States, United Kingdom

Portfolio highlights

Nomono — Nomono offers an all-in-one portable podcast kit, the Sound Capsule, designed for effortless recording and professional-quality audio. Simply press record to capture studio-quality sound anywhere, with no setup required. Enhance and edit your podcasts seamlessly with Nomono Cloud's AI-powered audio processing. Ideal for podcasters and broadcast journalists seeking a streamlined workflow and exceptional sound quality.
Hystar — Hystar develops polymer electrolyte membrane electrolyzers designed for large-scale green hydrogen production. Founded in 2020, Hystar's technology uses a unique cell design and process architecture that provides the ability to reduce electricity consumption and increase hydrogen output, enabling professionals to tackle various criticalenergy challenges and having the potential to reduce greenhouse gas emissions.
Hydrogen Mem-Tech — Hydrogen Mem-Tech aim is to make the green shift happen through our state-of-the-art hydrogen separation technology with carbon capture.

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Funding Round, Series B
Sweden, Norway, Austria

Portfolio highlights

SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.

Sarsia Seed AS is a Norwegian Seed Capital Fund which invests in Norwegian early phase technology companies within the energy/cleantech and biotechnology/life science sectors.The fund has a total capital of 333.5 million NOK (approx, 40 mEUR/50 mUSD) and is managed by Sarsia Seed Management AS. The management company advises theFund board regarding investment decisions. The Fundâ€:tm:s duration is expected to be 12 (+3) years.The Management Teamâ€:tm:s strength lay in its competence, experience and extensive national and international network of industrial players and co-investors. The Teamâ€:tm:s collective experience comprises an optimal balance between operations, business and specialised technology know-how, applied research, and entrepreneurship; elements which are actively used both in the vetting and follow-up of investments.

Investment focus

Biotechnology, Software, Pharmaceutical
Funding Round, Seed, Series A
Norway

Portfolio highlights

BerGenBio — BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
Sonoclear AS — At SonoClear, we are dedicated to improving the diagnostic accuracy of ultrasound to give neurosurgeons the clarity needed to make critical decisions in the resection of tumours.
Heimdall Power — Heimdall Power helps utilities optimize the power grid with state-of-the-art sensors and software, enabling real-time capacity management and situational awareness for a more efficient and reliable energy system.

Meneldor is a biopharmaceutical investment company .

Investment focus

Biotechnology, Health Care, Health Diagnostics
Series A, Seed, Debt Financing
Norway, Germany, United Kingdom

Portfolio highlights

Hemispherian — Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.
Aptamer Group — Rapid Optimer development as antibody alternatives for therapeutic, drug delivery, diagnostics and bioprocessing.
Atriva Therapeutics — Therapies against viral infections. First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.

Investment Company

Investment focus

Software, Health Care, Life Science
Pre-Seed
Norway

Portfolio highlights

Aurora Analytica — Founded in February 2023 and incorporated in January 2024, Aurora Analytica is a pioneering health technology company dedicated to optimizing the clinical trial lifecycle and accelerating the development of new treatment options. Our AI-powered platform provides strategic insights, site intelligence, and data-driven tools that enable biotech andpharmaceutical companies to design faster, smarter trials. A single platform that brings together essential assessments, the Aurora Suite™ consists of eleven interconnected modules that function collaboratively within a comprehensive analytics environment. Built on over 30 years of industry expertise, Aurora Analytica bridges the gap between innovation and execution—reducing costs, improving accuracy, and ultimately helping bring better therapies to patients, faster.

Investment Company

Investment focus

Software, Health Care, Life Science
Pre-Seed
Norway

Portfolio highlights

Aurora Analytica — Founded in February 2023 and incorporated in January 2024, Aurora Analytica is a pioneering health technology company dedicated to optimizing the clinical trial lifecycle and accelerating the development of new treatment options. Our AI-powered platform provides strategic insights, site intelligence, and data-driven tools that enable biotech andpharmaceutical companies to design faster, smarter trials. A single platform that brings together essential assessments, the Aurora Suite™ consists of eleven interconnected modules that function collaboratively within a comprehensive analytics environment. Built on over 30 years of industry expertise, Aurora Analytica bridges the gap between innovation and execution—reducing costs, improving accuracy, and ultimately helping bring better therapies to patients, faster.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

SafeHeal — SafeHeal is a clinical stage medical device manufacturer focusing on the development of anastomosis protection devices, including Colovac, for colorectal surgery.
Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
One Biosciences — One Biosciences unlocks routine analysis of tumor heterogeneity through AI-powered single-cell technologies, transforming precision medicine.

ProVenture invest in young digital technology startups in Norway. ProVenture have three seed funds and more than a billion NOK under management. ProVenture is a member of Norwegian Venture Association (NVCA).

Investment focus

Software, Oil and Gas, Information Technology
Seed, Funding Round, Series A
Norway, United States, India

Portfolio highlights

InfoTiles — InfoTiles provides real-time analytics solutions for Digital Water that span the water value chain, from supply & consumption to wastewater treatment and surveillance of waterways. InfoTiles unlocks data-driven planning, operations and maintenance.InfoTiles simplifies and automates the tedious steps of consolidating data, applying real-timeanalytics and machine learning so water utilities can turn insights into actions and benefit from more efficient, sustainable operations.
Wanda — Wanda.space is a technology and logistics start-up delivering space as a service.
Cimon Medical — Cimon Medical develops and manufactures novel Doppler ultrasound technology for healthcare and aim to become the market leader in continuous direct monitoring of blood-flow. The first product to be released in Q4 21 is NeoDoppler - non-invasive continuous monitoring of blood-flow in the brain of premature or critically ill infants.

We are an early stage venture capital firm based in Oslo, Norway.

Investment focus

Software, Information Technology, Artificial Intelligence
Pre-Seed, Seed, Funding Round
Norway, Denmark, United States

Portfolio highlights

Deckmatch — Tooling to drink from the firehose of data, that is your top of funnel (TOFU)
Take Take Take — Fantasy Chess is a platform that allows users to pick teams of real-world chess players, track their performance in tournaments, and receive points based on their achievement.
Starflow — Starflow goal is to create a scalable energy system that helps people achieve energy independence.

Sarsia is an early-stage venture capital investor that invest in science-based technology companies. It was founded in 2006 and is located in Bergen, Hordaland.

Investment focus

Biotechnology, Pharmaceutical
Series A
Norway

Portfolio highlights

Calluna Pharma — Join Calluna Pharma to transform therapeutics for inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, we can revolutionize patient care.
Flow Computing — Flow's Parallel Processing Unit (PPU) gives 100X CPU performance for demanding applications, such as locally-hosted AI and general-purpose parallel computing.

Gezina

Investment focus

Health Care, Biotechnology, Clinical Trials
Funding Round
Norway

Portfolio highlights

SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.

Nordic Impact invests in, supports, and builds businesses and funds based around technology. The company's goal is to make impact investing mainstream and mobilize all business and capital towards solving the big problems in the world while making great financial returns.

Investment focus

Chemical, Life Science, Visual Search
Seed
Norway

Portfolio highlights

Iris.ai — AI for scientific text understanding - Smart search, reading list analysis, auto-generated summaries, data extraction, chatbot with references.

Since 2011, we have built products with some of the most ambitious companies out there. From defining future homes with IKEA to building decentralised platforms with Coinbase.

Investment focus

Chemical, Software, Life Science
Seed, Angel
Norway

Portfolio highlights

Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
Iris.ai — AI for scientific text understanding - Smart search, reading list analysis, auto-generated summaries, data extraction, chatbot with references.

Norselab is a leading European impact investment house. We are dedicated to proving that impact is the future of investing across asset classes.

Investment focus

Software, SaaS, Agriculture
Seed, Funding Round, Series A
Norway, Switzerland, United States

Portfolio highlights

Looping — Looping offers reuse as a service by substituting reusable transport packaging for single-use plastic products. It produces long-lasting and reusable transport wrapping for building modules, housing modules, and steel containers.
Beefutures — Rooted in the beekeeping legacy and driven by expert engineering, Beefutures delivers accessible nature-based solutions to power a more sustainable world.
Wanda — Wanda.space is a technology and logistics start-up delivering space as a service.

World Wildlife Fund - The leading organization in wildlife conservation and endangered species. Learn how you can help WWF make a difference.

Investment focus

Seafood, Food Processing, Farming
Seed, Series A, Funding Round
Norway, Faroe Islands, United Kingdom

Portfolio highlights

OCEANIUM — OCEANIUM is a world-leading developer of innovative, functional seaweed ingredients to catalyse the seaweed industry for People Health and Ocean Health.
Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
Seaweed Solutions — Seaweed Solutions AS is one of Europe's largest seaweed farmers based in Norway. Our experience in seaweed farming dates back to 1978.

The Norwegian Research Council is the government's central research advisor. In 2012, the Research Council researched with more than 7 billion. This represents about 30% of R & D funding in the state budget.

Investment focus

Information Technology, Health Care, Biotechnology
Grant, Funding Round, Seed
Norway, Sweden

Portfolio highlights

CrayoNano — CrayoNano is a next generation semiconductor company. We specialize in nanotechnology that will enable a more sustainable and healthier life for tomorrow.
Elkem — Elkem is one of the world’s leading companies for environment responsible production of materials. Its principal products are silicon, silicones, ferrosilicon, foundry alloys, carbon materials and microsilica.Elkem has 24 production facilities in Europe, North and South America, Africa and Asia, as well as an extensive network of sales officesand agents covering the most important markets.
Aqualung Carbon Capture — Aqualung Carbon Capture provides industrial scale carbon capture units to speed up decarbonisation and mitigate carbon emissions.

Dynamk Capital is a New York headquartered growth equity and venture capital firm investing in life science industrials: tools, technologies and services that are critical for the discovery, development and production of life-saving therapies. Venture capital for Life Science tools.

Investment focus

Biotechnology, Medical, Health Care
Series A, Seed, Series B
United States, Canada, Norway

Portfolio highlights

CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.

Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.

Investment focus

Beauty, Medical, Biotechnology
Private Equity, Series A, Series D
Norway, Denmark, Switzerland

Portfolio highlights

Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy' is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
Galecto — Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

CoFounder is a management and investment company for technology companies with great growth potential. They are experienced entrepreneurs and business developers who provide management resources and early-stage capital. They work with spin-offs from both research and industrial environments, as well as standalone entrepreneurial companies.

Investment focus

Manufacturing, Industrial, SaaS
Seed, Funding Round, Series A
Norway

Portfolio highlights

Nicoustic — Nicoustic developed accurate, non-intrusive technology for separator-level measurement based on Guided Ultrasonic Waves. Their technique uses guided ultrasonic waves to measure the amounts of solids and liquids using sensors. It is being developed to measure the interface layers between emulsion and foam.Nicoustic's prototype is the outcomeof 20 years of study at the German Fraunhofer IKTS and a response to a challenge put forth by Equinor, the largest energy company in Norway.
Aviant — Delivering full-stack drone services that enables autonomous and on-demand transport of cargo.
Receipts — Any cashier system can now identify customers and send digital receipts to their mobile banking.

CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership working to accelerate the development of vaccines and other

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Seed, Funding Round
United States, United Kingdom, India

Portfolio highlights

aVaxziPen — Thermally Stable Solid Dose Needle Free Vaccines
Aspen Pharmacare — Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets
Gennova Biopharmaceuticals — Gennova Biopharmaceuticals is a biotechnology company that develops biotherapeutics and provides product development programs.

Glastad Holding is a family-owned company whose roots can be traced back to the shipping industry in the early 20th century. Today, Glastad Holding is a thriving investment company with three subsidiaries: Glastad Farsund - real estate, Mosvolds Rederi - shipping, and Glastad Invest - private equity and listed investments. Glastad Holding aims toexert active and long term ownership.

Investment focus

Health Care, Biotechnology, Clinical Trials
Funding Round
Norway

Portfolio highlights

SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.

Making Venture Happen. Televenture is one of the leading venture capital companies in Norway.

Investment focus

Manufacturing, Software, Information Technology
Funding Round, Seed, Series A
Norway, United States

Portfolio highlights

CrayoNano — CrayoNano is a next generation semiconductor company. We specialize in nanotechnology that will enable a more sustainable and healthier life for tomorrow.
Genetic Analysis — Genetic Analysis AS (GA) has the goal of being a leader within the field of molecular diagnostics of diseases related to gut imbalances. By utilizing the DNA-based GA-map™ array technology, profiles of a patient’s gut microbiota is quickly generated and can be related to various health conditions. Genetic Analysis has developed a DNA-basedtechnology platform that allows for simultaneous analysis of a large number of similarities (but not identical) gene fragments in one reaction. The company’s focus is to utilize this technology platform to identify variations in the hundreds of different bacteria that exist in the gut (large and small intestine). The GA - map makes it possible, for the first time, to offer a diagnostic solution – including early detection - for many diseases that are affected by imbalances in the gut microbiota. Genetic Analysis will offer kits and services for a wide range of applications.
Stingray Marine Solutions — Stingray Marine Solutions is a Norwegian technology firm that produces a laser unit which, when lowered into salmon farming pens, kills sea lice. It is based on entrepreneur Esben Beck’s patented idea in 2010 for salmon louse removal using camera vision and laser. It all started with Esben Beck and a lathe in his basement in 1999. After more than10 years of deliveries to oil, gas and offshore companies, he decided to invest in his own products. He decided to found and develop his own salmon louse project, where design, production, software development, testing, and installation were carried out by using in-house resources.Stingray is based in Oslo, Norway.

PAACS Invest is a privately owned Norwegian investment firm that focuses on active investments in healthcare and technology with a focus on sustainability.

Investment focus

Consulting, Health Care, Biotechnology
Seed
Norway

Portfolio highlights

Hemispherian — Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.

DNB is a financial services group that offers financial services through mobile, online banking, bank offices, and international offices. The Group provides a full range of financial services, including loans, savings, advisory services, insurance, and pension products for retail and corporate customers. The company’s personal banking products andservices include savings and investment products.DNB offers its products and services to various sectors, including financial institutions, energy, manufacturing, healthcare, packaging, and forest products, shipping, offshore, and logistics, seafood, and telecom, media, and technology. They also distribute its products and services through its branches, in-store postal and banking outlets, and post office counters.DNB was founded in 1822 and is headquartered in Oslo, Norway.

Investment focus

Energy, Banking, Software
Funding Round, Seed, Post-IPO Debt
Norway, Sweden, Denmark

Portfolio highlights

Mowi — Mowi, a seafood company, produces and supplies farmed salmon products worldwide. It operates through three segments: Feed, Farming, and Sales and Marketing. Mowi is involved in the salmon feed production, salmon farming and primary processing, and seafood secondary processing activities. It offers whole gutted fish, including Label Rouge andorganic salmon; and white fish and other seafood products, as well as fillets, steaks, cutlets, portions, loins, kebabs, and steak combos. Mowi also provides value added products, such as breaded, pre-fried, dusted, marinated, grilled, battered, topped, filled with sauce, delicatessen, fresh fish ready meal, and smoked fish products. It offers its products under the Pieters, The Irish Organic Salmon Company, Rebel Fish, Sterling, Olav's, Supreme Salmon, Ducktrap River, Kritsen, Donegal Silver, Harbour Salmon, Appeti’Marine, Mowi, Laschinger, and Admiral's brands. Marine Harvest that began operation in 1965 became Mowi in December 2018. It has its headquarters in 1965, with its headquarters in Bergen in Norway.
Scandi Standard — Welcome to Scandi Standard. We want to inspire you to choose chicken: a good, healthy choice, which is ideal for today’s consumers. We sell the finest Swedish, Danish, Norwegian and Finnish chicken under the Kronfågel, Danpo, Den stolte Hane and Naapurin Maalaiskana brands. We are the leading chicken producer in the Nordic region, serving thedomestic and export markets.In June 2013, we created the Nordic region's market-leading chickenbased product group when Scandi Standard was established. The Company was created by gathering the largest poultry operations in the region into one collective group. At present, the Group has an annual turnover of approximately SEK 5.2 billion and almost 1,700 employees.
Cypress Creek Renewables — Cypress Creek Renewables is committed to making the world cleaner and healthier. From development to operation, we create and operate valuable solar and storage projects that benefit communities for decades.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
Eeden — Eeden engages in the manufacture and supply of textiles.
Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.

Project Sandwater is a fresh take on venture investments within the Nordics and beyond.

Investment focus

Medical, Consulting, Life Science
Series A
Norway, The Netherlands

Portfolio highlights

Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
United States, United Kingdom, France

Portfolio highlights

Glycomine — We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.
Arga Medtech — Novel Sine Wave Technology Promises Significant Advantages Over Existing Pulsed Field Cardiac Ablation Systems
Relief Cardiovascular — Relief Cardiovascular is an inQB8 medical technologies portfolio company developing a revolutionary smart implant to decongest heart failure patients.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Draig Therapeutics — Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses.
ORIC Pharmaceuticals — ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments.

Protonic Partners is an investment firm.

Investment focus

SaaS, Biometrics, Information Services
Seed
Norway

Portfolio highlights

Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.

Advent Venture Partners is one of Europe's most successful growth and venture capital investors in market-leading tech and life sciences businesses. They have designed their strategy, teams and funds so they can focus on backing a select few companies. They pride their selves on establishing true partnerships with entrepreneurs in order tobuild valuable businesses together.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
United Kingdom, United States, Switzerland

Portfolio highlights

Wiz — Organizations of all sizes and industries use Wiz to rapidly identify and remove the most critical risks in AWS, Azure, GCP, and Kubernetes so they can build faster and more securely.
WorldStores — Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories.ACHICA, the luxury flash-sale business, and baby specialistKiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.
Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.

InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.

Investment focus

Biotechnology, Health Care, Software
Funding Round, Series B, Series C
Sweden, Denmark, United States

Portfolio highlights

Silecs — PiBond manufactures materials used in electronic devices, including patterning materials for semiconductors and optical materials. We also develop complete solutions that allow our clients to focus on creating innovative products.
SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
Action Pharma — Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VCÂ´s in Scandinaviaaccording to track record of value created for their investors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Funding Round, Series A
Sweden, Norway, United States

Portfolio highlights

GLO — glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who haspublished more than 500 papers related to this technology.glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications.glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications.glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized.glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.
SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
Sol Voltaics — Founded in 2007, Sol Voltaics AB is a venture-backed, development-stage nanotechnology company focused on development and commercialization of highly efficient, third-generation photovoltaic concentrator solar cells based on its proprietary heterostructured nanowire epitaxial growth and process technologies.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.

Investors by industry